Table 2 Comparisons of clinical manifestations and laboratory features in whole-cohort AML patients.
From: HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia
Patients parameters | HSPG2 expression | |||
|---|---|---|---|---|
All patients (n = 151) | Low (n = 49) | High (n = 102) | P | |
Sex, male/female | 78/73 | 26/23 | 52/50 | 0.863 |
Median age, year, (range) | 48 (12–83) | 42.5 (20–81) | 50 (12–83) | 0.287 |
Median WBC × 109/L, (range) | 5.19 (0.35–262.2) | 3.97 (0.36–92.78) | 8.47 (0.35–262.2) | <0.001 |
Median HGB, g/L, (range) | 79 (11–183) | 93.5 (41–183) | 74 (11–148) | 0.002 |
Median PLT, ×109/L, (range) | 56 (3–491) | 105 (4–491) | 42 (3–319) | 0.001 |
BM blasts, % (range) | 36 (0–96) | 2 (0–91) | 60 (1–96) | <0.001 |
FAB classification | 0.933 | |||
M1 | 9/151 (6.0%) | 2/49 (4.1%) | 7/102 (6.9%) | |
M2 | 44/151 (29.1%) | 19/49 (38.8%) | 25/102 (24.5%) | |
M3 | 20/151 (13.2%) | 4/49 (8.2%) | 16/102 (15.7%) | |
M4 | 20/151 (13.2%) | 4/49 (8.2%) | 16/102 (15.7%) | |
M5 | 29/151 (19.2%) | 11/49 (22.4%) | 18/102 (17.6%) | |
M6 | 4/151 (2.6%) | 1/49 (2.0%) | 3/102 (2.9%) | |
M7 | 1/151 (0.7%) | 0/49 (0.0%) | 1/102 (1.0%) | |
Others | 7/151 (4.6%) | 1/49 (2.0%) | 6/102 (5.9%) | |
sAML | 17/151 (11.3%) | 7/49 (14.3%) | 10/102 (9.8%) | |
Karyotypes | 0.069 | |||
Normal | 48/151 (31.8%) | 26/49 (53.1%) | 22/102 (21.6%) | |
t (15;17) | 6/151 (4.0%) | 0/49 (0.0%) | 6/102 (5.9%) | |
t (8;21) | 11/151 (7.3%) | 5/49 (10.2%) | 6/102 (5.9%) | |
Other abnormal karyotypes | 23/151 (15.2%) | 8/49 (16.3%) | 15/102 (14.7%) | |
Complex karyotype (>3 chromosomal abnormalities) | 5/151 (3.3%) | 1/49 (2.0%) | 4/102 (3.9%) | |
No data | 58/151 (38.4%) | 9/49 (18.4%) | 49/102 (48.0%) | |
Gene mutation | ||||
WT1 | 77/151 (51.0%) | 30/49 (61.2%) | 47/102 (46.1%) | 0.086 |
NPM1 | 12/151 (7.9%) | 4/49 (8.2%) | 8/102 (7.8%) | 1.000 |
DNMT3A | 10/151 (6.6%) | 2/49 (4.1%) | 8/102 (7.8%) | 0.501 |
C-KIT | 11/151 (7.3%) | 5/49 (10.2%) | 6/102 (5.9%) | 0.506 |
FLT3-ITD | 7/151 (4.6%) | 1/49 (2.0%) | 6/102 (5.9%) | 0.429 |
IDH1/2 | 17/151 (11.3%) | 3/49 (6.1%) | 14/102 (13.7%) | 0.270 |
AML1-ETO | 24/151 (15.9%) | 12/49 (24.5%) | 12/102 (11.8%) | 0.058 |
Treatment regimen | ||||
Chemotherapy-only | 110/151 (72.8%) | 31/49 (63.3%) | 79/102 (77.5%) | 0.066 |
HSCT | 41/151 (27.2%) | 18/49 (36.7%) | 23/102 (22.5%) | |
Response | ||||
CR | 70/151 (46.4%) | 30/49 (61.2%) | 40/102 (39.2%) | 0.011 |
